CSL Shares Test Resistance, As Earnings Await

For those who haven’t been watching, CSL shares (ASX:CSL) have been quietly rebuilding momentum, adding 46% since the start of June, and 13.3% over the past month of trading.

With the stock having recaptured A$130, CSL’s share price is now testing resistance at A$140 on an intraday basis as bulls look to break higher. The current share price at A$137.52, down 20% YTD may not appear all to exciting for those just checking the 2026 screens, yet for those who have been following the name, there has been plenty to like about the rebound.

The rally marks a sharp reversal in sentiment for Australia’s largest healthcare stock following a brutal May sell-off that saw the shares collapse to a low of A$90s after the company delivered a guidance downgrade and flagged approximately US$5 billion in additional impairments. Markets are now weighing whether the rebound represents a genuine turnaround or merely a technical bounce within a longer-term de-rating of the plasma products and vaccines manufacturer.

What has been driving CSL shares this year?

The current price action follows one of the most turbulent periods in CSL’s listed history. On 11 May 2026, interim chief executive Gordon Naylor released the findings of his 90-day strategic review, slashing full-year fiscal 2026 revenue guidance to around US$15.2 billion in constant currency terms and cutting net profit after tax and amortisation expectations to approximately US$3.1 billion, excluding restructuring costs and impairments.

The company attributed roughly US$300 million of the revenue shortfall to channel destocking in US immunoglobulin markets, US$200 million to lower market values in China albumin despite stable volumes and share, and a further US$150 million to a combination of Middle East conflict impacts, slower-than-expected uptake of gene therapy HEMGENIX, and competitive pressure in iron deficiency therapies.

The guidance reduction came on top of an already disappointing half-year result released in February 2026, which showed net profit plunging approximately 81% year-on-year for the six months to 31 December 2025. That result sent the shares to an eight-year low and prompted widespread concern about execution missteps following the 2022 acquisition of Swiss pharmaceutical business Vifor Pharma.

That announcement compounded those fears by revealing that CSL expected to book around US$5 billion of additional pre-tax, non-cash impairments across fiscal 2026 and 2027, primarily related to Vifor intangible assets and underutilised property, plant and equipment. Combined with impairments already recognised at the half-year mark, the total writedowns are estimated to exceed US$6.5 billion.

Markets reacted violently to the May update, with the stock falling to levels not seen since the mid-2010s, with forward price-to-earnings multiples compressing to the low double digits and enterprise value-to-EBITDA ratios dipping below 10 times on a forward basis. Yet the very severity of that drawdown appears to have set the stage for the subsequent rebound.

The bounce

From early June onwards, a growing cohort of institutional and retail investors began arguing that CSL had become oversold, pointing to the company’s oligopolistic position in global plasma collection and fractionation, structurally sound demand for immunoglobulin products growing at mid-to-high single digits, and the likelihood that management had taken a conservative, kitchen-sink approach to resetting expectations under interim leadership. The narrative shifted from capitulation to accumulation, with an increasing feeling that much of the bad news had been crystallised in the guidance cut and was reflected in the share price.

The company’s transformation programme, which targets hundreds of millions of dollars in sustainable cost savings has also featured prominently for bulls. Management has emphasised operational simplification, portfolio pruning, and improved commercial execution, particularly around newer product launches. While the financial benefits of these initiatives are expected to materialise later than originally hoped, the May review confirmed that the underlying strategic work is progressing.

What next for CSL?

From a technical perspective, the share price has recaptured the psychologically important A$130 level and is now consolidating just below A$140, a level that has acted as intraday resistance in recent sessions. The upcoming full-year fiscal 2026 results, expected next week (18th), loom as the next major test.

For now, CSL shares are caught between the pull of recent disappointments and the attraction of trading at a historically steep discount, with bulls and bears locked in battle just below the A$140 mark. With the stock up 4% this week heading into the final trading session, it looks like it will be three consecutive weeks of gains, and third month if the trend holds.